Parameter
| Biomarker | Helicobacter pylori (H. pylori) | Full name | Helicobacter pylori | Molecular Type | Pathogens (bacteria) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Susceptibility, early diagnosis | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Gastric mucosa tissues (pathological staining, PCR), serum (H. pylori antibody detection), feces (antigen detection) | ||
| Pathobiological Mechanisms | Class I carcinogens, about 70%-90% of gastric cancer are related to H. pylori infection. Virulence factors such as CagA and VacA induce chronic inflammation, gastric mucosal atrophy, intestinal metaplasia, and finally develop into gastric cancer by activating the NF-κB and Wnt pathways | ||||
| Clinical Availability Status | Clinical use (risk assessment/prevention) : it can be used for the screening of high-risk population of gastric cancer. Eradication therapy in H. pylori positive patients can reduce the risk of gastric cancer | ||||
| Notes and Dynamics | As a key marker for primary prevention of gastric cancer, the risk of gastric cancer in patients infected with CagA positive strains is significantly increased. Eradication therapy can reduce the risk of gastric cancer by 30%-40%. Combined detection of serum PG and G-17 can improve the accuracy of screening gastric precancerous lesions | ||||